aberrations.112 At last, the alternative BTK inhibitor acalabrutinib was just lately authorised from the FDA (not through the EMA still) as frontline therapy in perspective of the outcomes of a stage III trial evaluating acalabrutinib compared toGenetic susceptibility mechanisms. Most susceptibility loci map to non-coding regions in the genome, are